Détail de l'auteur
Auteur Jasmin B |
Documents disponibles écrits par cet auteur (8)
trié(s) par (Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) | Mettre toutes les notices dans le panier | Faire une suggestion | Ajouter un critère de recherche
Article
5th International Congress of Myology (14-18 March 2016; Centre convention, Lyon, France), Collectivité éditrice ; Jasmin B, Auteur ; Furling D, Auteur ; Bassez G, Auteur | AFM-TELETHON | 16/03/2016Article
The RNA-binding protein STAUFEN1 is increased in DM1 skeletal muscle and regulates PRE-MRNA splicing
4th International Congress of Myology, 4ème colloque international de Myologie (9-13 mai 2011; Lille (France)) ; Ravel Chapuis A ; Bélanger G ; Yadava R ; Mahadevan M ; Desgroseillers L ; Coté J ; Jasmin B | AFM-TELETHON | 2011Myotonic Dystrophy (DM1) is caused by an expansion of CTG repeats in the 3' untranslated region (3'UTR) of DMPK mRNA. The expanded mRNA aggregates in the nucleus and becomes toxic to cells by sequestering and/or misregulating RNA-binding protein[...]Article
Mousavi K ; Ravel Chapuis A ; Jasmin B | 2008Muscle-derived BDNF has long been thought to serve as a retrograde trophic factor for innervating motor neurons throughout their lifespan. However, our recent studies have shown that BDNF is not enriched at the neuromuscular junction in adult sk[...]Article
Congrès international de myologie 2008 (International Congress of Myology 2008; 26-30 mai 2008; Marseille, France) ; Miura P ; Coriati A ; Sarkar M ; Andrews M ; Holcik M ; Jasmin B | 2008Glucocorticoids are currently the only drugs recognized to benefit Duchenne muscular dystrophy (DMD) patients. The mechanisms that underlie the beneficial effects still remain incompletely understood. In agreement with previous observations, we [...]Article
Colloque jeunes chercheurs (7 mars 2008; EVRY - Centre conférence Génocentre Evry) ; Miura P ; Coriati A ; Sarkar M ; Andrews M ; Holcik M ; Jasmin B | 2008Glucocorticoids are currently the only drugs recognized to benefit Duchenne muscular dystrophy (DMD) patients. The mechanisms that underlie the beneficial effects still remain incompletely understood. In agreement with previous observations, we [...]Article
Congrès international de myologie 2008 (International Congress of Myology 2008; 26-30 mai 2008; Marseille, France) ; Ravel Chapuis A ; Bélanger G ; Coté J ; Thornton C ; Desgroseillers L ; Jasmin B | 2008Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder that results in several characteristic symptoms including myotonia, muscle weakness and wasting, pain, cardiac defects, cataracts, cognitive impairments, and endocrine abnormaliti[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Chakkalakal J ; Jasmin B | 2005Communication n° 421. Introduction : We have previously shown that slow/oxidative muscle fibers contain significantly more utrophin in comparison to fast/glycolytic fibers (Gramolini et al., 2001). More recent studies have implicated calcineurin[...]Article
Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France) ; Miura P ; Jasmin B ; Thompson J ; Chakkalakal J ; Holcik M | 2005Communication n° 416. Introduction : A therapeutic strategy to treat Duchenne muscular dystrophy (DMD) is to upregulate utrophin expression in the muscles of affected patients. Our previous studies have shown that during muscle regeneration, utr[...]